{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:54:18Z","timestamp":1761562458646},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.resinv.2018.12.002","type":"journal-article","created":{"date-parts":[[2018,12,30]],"date-time":"2018-12-30T00:31:23Z","timestamp":1546129883000},"page":"165-171","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Lung transplant candidates with idiopathic pulmonary fibrosis and long-term pirfenidone therapy: Treatment feasibility influences waitlist survival"],"prefix":"10.1016","volume":"57","author":[{"given":"Shin","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaroh","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisao","family":"Higo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kurosaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Otani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiichiro","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaomi","family":"Yamane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuyuki","family":"Kiura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Toyooka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Oto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2018.12.002_bib1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1164\/ajrccm.157.1.9704130","article-title":"Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis","volume":"157","author":"Bjoraker","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2018.12.002_bib2","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1164\/ajrccm.164.7.2003140","article-title":"Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model","volume":"164","author":"King","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2018.12.002_bib4","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1164\/rccm.200701-044OC","article-title":"Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003","volume":"176","author":"Olson","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2018.12.002_bib5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s12016-010-8244-9","article-title":"Therapeutic update in idiopathic pulmonary fibrosis","volume":"44","author":"Chan","year":"2013","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.resinv.2018.12.002_bib6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0140-6736(97)06405-2","article-title":"Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease","volume":"351","author":"Hosenpud","year":"1998","journal-title":"Lancet"},{"issue":"Suppl 9","key":"10.1016\/j.resinv.2018.12.002_bib7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1600-6135.2004.00401.x","article-title":"Thoracic organ transplantation","volume":"4","author":"Pierson","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.resinv.2018.12.002_bib8","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/1471-2466-14-139","article-title":"Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature","volume":"14","author":"Kistler","year":"2014","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.resinv.2018.12.002_bib9","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2018.12.002_bib10","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2018.12.002_bib11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1183\/09059180.00008513","article-title":"Pirfenidone: an update on clinical trial data and insights from everyday practice","volume":"23","author":"Kreuter","year":"2014","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.resinv.2018.12.002_bib12","first-page":"211","article-title":"Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis","volume":"289","author":"Iyer","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.resinv.2018.12.002_bib13","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1165\/rcmb.2005-0452OC","article-title":"Pirfenidone modulates airway responsiveness, inflammation, and remodeling after repeated challenge","volume":"35","author":"Hirano","year":"2006","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.resinv.2018.12.002_bib14","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.resinv.2018.12.002_bib15","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1164\/rccm.200404-571OC","article-title":"Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"171","author":"Azuma","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2018.12.002_bib16","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1164\/rccm.200211-1311OC","article-title":"Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis","volume":"168","author":"Collard","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2018.12.002_bib17","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1164\/rccm.200209-1112OC","article-title":"Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia","volume":"168","author":"Flaherty","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2018.12.002_bib18","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1378\/chest.127.1.171","article-title":"Analyses of efficacy end points in a controlled trial of interferon- gamma1b for idiopathic pulmonary fibrosis","volume":"127","author":"King","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2018.12.002_bib19","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1164\/rccm.201105-0840OC","article-title":"Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference","volume":"184","author":"du Bois","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2018.12.002_bib20","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1183\/09031936.00005209","article-title":"Pirfenidone in idiopathic pulmonary fibrosis","volume":"35","author":"Taniguchi","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2018.12.002_bib21","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.healun.2009.04.024","article-title":"Impact of U.S. Lung Allocation Score on survival after lung transplantation","volume":"28","author":"Merlo","year":"2009","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.resinv.2018.12.002_bib22","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1183\/09059180.00001111","article-title":"Antifibrotic activities of pirfenidone in animal models","volume":"20","author":"Schaefer","year":"2011","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.resinv.2018.12.002_bib23","article-title":"Histopathologic and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib","author":"Zhang","year":"2018","journal-title":"Histopathology"},{"key":"10.1016\/j.resinv.2018.12.002_bib24","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12890-016-0308-z","article-title":"Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series","volume":"16","author":"Delanote","year":"2016","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.resinv.2018.12.002_bib25","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.healun.2017.07.002","article-title":"Outcome of lung transplantation in idiopathic pulmonary fibrosis with previous anti-fibrotic therapy","volume":"37","author":"Leuschner","year":"2018","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.resinv.2018.12.002_bib26","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1159\/000479976","article-title":"An open-label study of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (RECAP)","volume":"94","author":"Costabel","year":"2017","journal-title":"Respiration"},{"key":"10.1016\/j.resinv.2018.12.002_bib27","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1378\/chest.128.1.407","article-title":"Pro\/Con debate: lung allocation should be based on medical urgency and transplant survival and not on waiting time","volume":"128","author":"Egan","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2018.12.002_bib28","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.resinv.2017.03.002","article-title":"Clinical characteristics of Japanese candidates for lung transplant for interstitial lung disease and risk factors for early death while on the waiting list","volume":"55","author":"Higo","year":"2017","journal-title":"Respir Investig"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534518301825?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534518301825?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T15:55:31Z","timestamp":1551887731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534518301825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S2212534518301825"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2018.12.002","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lung transplant candidates with idiopathic pulmonary fibrosis and long-term pirfenidone therapy: Treatment feasibility influences waitlist survival","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2018.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}